Mirum Pharmaceuticals (MIRM)
(Real Time Quote from BATS)
$53.38 USD
+1.54 (2.97%)
Updated Aug 6, 2025 12:50 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MIRM 53.38 +1.54(2.97%)
Will MIRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Other News for MIRM
Here are the major earnings after the close Wednesday
Earnings Scheduled For August 6, 2025
ClearBridge Small Cap Growth Portfolios Q2 2025 Commentary
ClearBridge Small Cap Growth Fund Q2 2025 Commentary
Mirum Pharmaceuticals Inc (MIRM) Announces Upcoming Second Quarter 2025 Financial Results | ...